BrightSens Diagnostics


Brightsens Diagnostics develops a new generation of molecular diagnostic tests that are simple to use, rapid, and cost-effective, aimed at point-of-care testing for screening, diagnosis, and patient monitoring. Their innovative technology leverages nanoparticle-based fluorescence amplification without enzymatic amplification, suitable for both solid biopsies and liquid samples, and compatible with common laboratory instruments and smartphone applications.

Industries

analytics
biotechnology
pharmaceutical

Nr. of Employees

small (1-50)

BrightSens Diagnostics

Illkirch-graffenstaden, Alsace, France, Europe


Products

miRNA screening and point-of-care assays for oncology

Molecular tests targeting key microRNAs intended for cancer screening, early diagnosis, and patient monitoring in point-of-care or laboratory settings.

Rapid viral RNA detection assays for surveillance

Rapid molecular assays for detection of viral RNA, described for SARS-CoV-2 and variants, designed to offer PCR-comparable sensitivity at lower cost for surveillance and diagnosis.


Services

Custom probe design and production

Design and manufacture of nucleic acid probes tailored to customer-specified targets to support R&D and validation workflows.

Partnerships for assay development and validation

Collaborative development with clinical and academic partners to adapt and validate assays for specific clinical applications.

Expertise Areas

  • Molecular diagnostics
  • Point-of-care testing
  • Nanoparticle probe design
  • miRNA biomarker assay development
  • Show More (4)

Key Technologies

  • Ultrabright fluorescent nanoparticle probes
  • FRET-based fluorescence amplification
  • Nucleic acid hybridization assays
  • miRNA detection assays
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.